XM does not provide services to residents of the United States of America.

Technical Analysis – USDCAD trades higher, bounces off a key trendline



  • USDCAD is edging higher today, a tad above 1.3977
  • It bounced off the September 25, 2024 trendline
  • Momentum indicators are gradually turning bearish

USDCAD is edging higher today, trading a tad above the October 13, 2022 high at 1.3977. CAD bulls’ latest attempt to push USDCAD below the September 25, 2024 ascending trendline failed, with the pair quickly climbing higher. The US dollar also got a boost from Thursday’s stronger US data prints, geopolitics and the hawkish rhetoric from Fed members. For the current bullish trend to remain in place, a new peak, above the four-year high of 1.4104, is probably needed.

Meanwhile, momentum indicators are gradually turning bearish. Specifically, the Average Directional Movement Index (ADX) is edging lower towards its midpoint, and thus pointing to a weaker bullish trend in USDCAD. Additionally, the stochastic oscillator has broken below its oversold territory (OS) and is heading aggressively lower. Should this move continue, it would be seen as a strong bearish signal. Interestingly, the RSI remains above its midpoint, but it shows little appetite for a sizeable move higher.

Should the bears remain confident, they could try to finally push USDCAD below both the October 13, 2022 high at 1.3977 and the September 25, 2024 trendline. They could then test the support set by the November 1, 2024 high at 1.3898. Even lower, the busy 1.3807-1.3854 region could prove tougher to overcome than currently imagined.

On the other hand, the bulls will try to drive USDCAD above the 1.3977 level and then gradually push it higher towards the November 15 high at 1.4104. If successful in breaking above this level, they could have the chance to record a new cycle high.

To sum up, USDCAD bears tried to have staged another selloff, but the US dollar-positive newsflow and a key upward sloping trendline have pushed USDCAD higher.

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.